ENDE

Account

Overview · Filed: —

UPC_APP_17291/2025

NOVEL ANTITUMORAL USE OF CABAZITAXEL

Procedural & sub-applicationsOther ProceduralMunich LDGeneric application—

Overview Decisions Documents Timeline

Parties

Claimants

Sanofi SA(Sanofi Group)
Sanofi Winthrop Industrie(Sanofi Group)
Sanofi-Aventis GmbH(Sanofi Group)
Sanofi Belgium(Sanofi Group)
Sanofi-Aventis Deutschland GmbH(Sanofi Group)
Sanofi S.r.l.(Sanofi Group)
Sanofi B.V.(Sanofi Group)
Sanofi - Produtos Farmaceuticos Lda(Sanofi Group)
Sanofi AB(Sanofi Group)
Sanofi A/S(Sanofi Group)

Reps: Frédéric Chevallier (Herbert Smith Freehills)

Respondents

Accord Healthcare S.L.U.
Accord Healthcare GmbH (AT)
Accord Healthcare B.V.
Accord Healthcare GmbH (DE)
Accord Healthcare Italia Srl
Accord Healthcare, Unipessoal Lda.
Accord Healthcare AB
STADA Nordic ApS

Reps: Jules Fabre (Pinsent Mason); Arjan Reijns (Pinsent Mason); Louise Millot (Pinsent Mason)

Judges

Matthias ZigannPresiding judge and judge-rapporteur

Patents

EP 2 493 466

CPC codes: A61K38/193, A61K31/573, A61P35/04, A61K31/164, A61K31/56, A61P43/00, A61P13/08, A61P15/00, A61K31/337, A61P35/00, A61K45/06, A61P25/16

Sector: Pharmaceutical & Medical

Outcome

Procedural only

Filed: —

First decided: May 8, 2025

Language: —